Contact
Please use this form to send email to PR contact of this press release:
Junshi Biosciences Announces the sNDA Approval of Toripalimab for the 1st-line Treatment of Melanoma
TO:
Please use this form to send email to PR contact of this press release:
Junshi Biosciences Announces the sNDA Approval of Toripalimab for the 1st-line Treatment of Melanoma
TO: